TherapeuticsMD, Inc.
TXMDTherapeuticsMD, Inc. in brief
TherapeuticsMD, Inc. is a listed company in the Pharmaceutical industry, based in Boca Raton, Florida, USA. Its market value was $23 M on 14 October 2026, which makes it the 23,947th largest listed company in the world and the 4,123rd largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net loss of $1 M. Marlan D. Walker is its chief executive. By market, the largest shares of its 2025 sales came from USA (59%). Its shares trade under the symbol TXMD (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About TherapeuticsMD, Inc.
TherapeuticsMD is a Innovative Pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. It develops product to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health and menopause management. The company annual revenue is 19.3 million USD and 241 employees as on 2020. The headquarters is in USA.
TherapeuticsMD, Inc. timeline
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1997
- ✎Renamed Croff Enterprises IncFormerly Croff Oil Co.
- 2009
- ✎Renamed AMHN, Inc.Formerly Croff Enterprises Inc.
- 2011
- ✎Renamed TherapeuticsMD, Inc.Formerly AMHN, Inc..
- 2022
- 💰Record revenue of $70 millionFY2022, the highest of the 7 years on record.
Events of TherapeuticsMD, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,271 (Jan 2020) · #2,796 (Jan 2021) · #4,018 (Jan 2022) · #4,739 (Dec 2022) · #4,840 (Jul 2023) · #4,310 (Jan 2024) · #2,277 (Mar 2026) · #3,912 (Aug 2026) · #4,090 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 174.5×
- Price / sales (TTM)
- 6.1×
- Price / book
- 0.8×
- Free cash flow yield
- -629.0%
- Net margin (TTM)
- 3.5%
- Operating margin
- -145.4%
- Return on equity
- 0.5%
- Liabilities / assets
- 28.6%
- Net debt
- $123M
- Revenue growth
- +71.6%
- R&D / revenue
- 16.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3M | +71.6% | $-4M | $-1M | -18.9% |
| Dec 2024 | $2M | +35.4% | $-6M | $-2M | -123.9% |
| Dec 2023 | $1M | -98.1% | $-9M | $-10M | -790.8% |
| Dec 2022 | $70M | — | $1M | $112M | 160.1% |
| Dec 2021 | — | — | $-80M | $-172M | — |
| Dec 2020 | $65M | +30.7% | $-156M | $-184M | -282.9% |
| Dec 2019 | $50M | +208.4% | $-151M | $-176M | -354.8% |
| Dec 2018 | $16M | — | $-130M | $-133M | -823.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $2M | — | — | $-0.05 | — |
| Dec 2024 | $1M | — | — | $-0.19 | — |
| Dec 2023 | $-23M | — | — | $-0.99 | — |
| Dec 2022 | $9M | — | — | $11.96 | — |
| Dec 2021 | $-143M | $0M | $-143M | $-21.66 | — |
| Dec 2020 | $-159M | $0M | $-160M | $-0.67 | — |
| Dec 2019 | $-166M | $2M | $-168M | $-0.72 | — |
| Dec 2018 | $-107M | $0M | $-107M | $-0.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+61.5% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 20, 2026DEF 14AProxy statement
- Nov 13, 202610-QQuarterly report · period to Sep 2026
- Nov 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 1, 202610-K/AAnnual report (amended) · period to Dec 2025
- Mar 30, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Mar 30, 202610-KAnnual report · period to Dec 2025
- Jan 21, 20268-KCurrent reportAuditor change
- Dec 16, 20258-KCurrent reportShareholder vote
Official filings of TherapeuticsMD, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $3 M
- Operating income
- $-4 M
- Net income
- $-1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $38 M
- Total liabilities
- $11 M
- Total equity
- $27 M
As of December-2025
Top 46 institutional investors in TherapeuticsMD, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 1,192,191 | 0 (0.00%) | 10.30% | $2 M | Nov 16, 2026 |
| 2 | Clearline Capital LP | 635,222 | 0 (0.00%) | 5.49% | $1 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 394,397 | +40,700 (+11.51%) | 3.41% | $1 M | Nov 13, 2026 |
| 4 | ADAR1 Capital Management, LLC | 342,447 | 0 (0.00%) | 2.96% | $1 M | Nov 16, 2026 |
| 5 | Tejara Capital Ltd | 327,282 | -17,200 (-4.99%) | 2.83% | $1 M | Nov 9, 2026 |
| 6 | Renaissance Technologies LLC | 142,199 | -4,400 (-3.00%) | 1.23% | $0 M | Nov 12, 2026 |
| 7 | Morgan Stanley | 128,977 | -240 (-0.19%) | 1.11% | $0 M | Nov 13, 2026 |
| 8 | BlackRock, Inc. | 115,145 | 0 (0.00%) | 0.99% | $0 M | Nov 13, 2026 |
| 9 | Geode Capital Management, LLC | 106,851 | +1,002 (+0.95%) | 0.92% | $0 M | Nov 6, 2026 |
| 10 | Citadel Advisors LLC | 64,787 | -21,308 (-24.75%) | 0.56% | $0 M | Nov 16, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 63,831 | 0 (0.00%) | 0.55% | $0 M | Nov 13, 2026 |
| 12 | HRT Financial LP | 42,103 | +27,376 (+185.89%) | 0.36% | $0 M | Nov 13, 2026 |
| 13 | State Street Corp | 30,100 | 0 (0.00%) | 0.26% | $0 M | Nov 12, 2026 |
| 14 | Dimensional Fund Advisors LP | 23,922 | +4,203 (+21.31%) | 0.21% | $0 M | Nov 4, 2026 |
| 15 | Northern Trust Corp | 18,556 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 16 | Bridgeway Capital Management, LLC | 16,705 | -295 (-1.74%) | 0.14% | $0 M | Nov 16, 2026 |
| 17 | Empowered Funds, LLC | 16,705 | New | 0.14% | $0 M | Nov 13, 2026 |
| 18 | Ashton Thomas Private Wealth, LLC | 16,581 | New | 0.14% | $0 M | Nov 3, 2026 |
| 19 | US Bancorp \de\ | 14,740 | +14,494 (+5891.87%) | 0.13% | $0 M | Nov 5, 2026 |
| 20 | XTX Topco Ltd | 10,683 | -10,563 (-49.72%) | 0.09% | $0 M | Nov 16, 2026 |
| 21 | Vanguard Global Advisers, LLC | 4,937 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 22 | UBS Group AG | 3,028 | -1,632 (-35.02%) | 0.03% | $0 M | Nov 10, 2026 |
| 23 | Tower Research Capital LLC (TRC) | 1,814 | +232 (+14.66%) | 0.02% | $0 M | Nov 16, 2026 |
| 24 | SBI Securities Co., Ltd. | 1,263 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 25 | Royal Bank Of Canada | 842 | +9 (+1.08%) | 0.01% | $0 M | Nov 16, 2026 |
All 46 institutional investors: 26 to 46, with who bought and sold →
Mutual funds holding TherapeuticsMD, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 244,317 | $1 M | 2.1% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 109,380 | $0 M | 0.95% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 65,183 | $0 M | 0.56% | <0.01% | −3.0% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 17,000 | $0 M | 0.15% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 15,320 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 14,835 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,826 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 The Gabelli ABC FundGabelli Funds, LLC | 3,600 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 3,612 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 3,076 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 745 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
As of Jul 31, 2026
Insider trading at TherapeuticsMD, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Tommy G. ThompsonDirector | Buy | +8,400 | $1.670 | $14 K | 23,179 | Form 4 |
| filed | Marlan D. WalkerChief Executive Officer | Buy | +490 | $1.000 | $490 | 73,639 | Form 4 |
| filed | Tommy G. ThompsonDirector | Buy | +325 | $1.000 | $325 | 14,779 | Form 4 |
| filed | Marlan D. WalkerChief Executive Officer | Buy | +1,167 | $0.860 | $1 K | 73,149 | Form 4 |
| filed | Marlan D. WalkerChief Executive Officer | Buy | +1,136 | $0.870 | $988 | 71,982 | Form 4 |
| filed | Gail K. NaughtonDirector | Option exercise | +8,500 | — | — | 8,500 | Form 4 |
| filed | Marlan D. WalkerChief Executive Officer | Option exercise | +3,467 | — | — | 66,032 | Form 4 |
| filed | Cooper C. CollinsDirector | Option exercise | +8,500 | — | — | 60,516 | Form 4 |
Markets and events: TherapeuticsMD, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-50 reverse split
Trading halts
- 2025-01-03 14:32 UTC, code LUDP, resumed 14:37 UTC
Fails to deliver
- : 193 shares at $1.96
- : 535 shares at $2.02
- : 54 shares at $2.19
- : 19 shares at $2.18
- : 2 shares at $2.11
TherapeuticsMD, Inc. scorecard#
Passes 5 of the 15 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.
Valuation1 of 2
Growth2 of 3
Profitability0 of 5
Financial health1 of 4
Shareholder returns1 of 1
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from TherapeuticsMD, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -145.4% | 1.8% | |
| Net margin | -18.9% | -1.5% | |
| Return on equity | -2.1% | -0.9% | |
| Revenue growth | 71.6% | 7.3% |
5of 7on the Piotroski tests of financial strength
- Net loss of $1 million, the 3th loss-making year in a row.
- Operating income covers the interest bill only -439.0 times.
TherapeuticsMD, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 3.0 | 1.8 | 1.3 | 70 | 2.6r | 65r | 50r | 16 | 17 | 19 | |
| Cost of revenue | — | — | — | 1.4 | 1.4r | 16r | 6.3r | 2.7 | 2.6 | 4.2 | |
| Gross profit | — | — | 1.3 | 69 | 1.2r | 49r | 43r | 13 | 14 | 15 | |
| Research and development | — | — | — | — | 7.1 | 10r | 20r | 27 | 34 | 54 | |
| Selling, general and administrative | — | 4.7 | 8.9 | — | — | 193 | 174 | 116 | 58 | 51 | |
| Selling and marketing | — | — | — | — | 108 | 117 | 114 | — | — | — | |
| General and administrative | 6.9 | 6.1 | 8.9 | 57r | 81r | 77 | 60 | — | — | — | |
| Operating expenses | 7.4 | 7.9r | 9.8 | 67 | 81r | 204r | 195r | 144 | 92 | 105 | |
| Operating income | −4.4 | −6.1r | −8.5 | 1.2 | −80r | −156r | −151r | −130 | −78 | −90 | |
| Interest and finance income | 0.1 | 0.1 | — | — | — | — | — | — | — | 0.0 | |
| Interest expense and finance costs | 0.0 | 0.0r | 0.3 | 0.2r | 33 | 29r | 17r | 4.7 | — | — | |
| Other non-operating income (expense) | 3.7 | 3.8r | 0.8 | −0.1 | 0.3r | −28r | −25r | −2.4 | 0.7 | 0.4 | |
| Income before tax | −0.7 | −2.3 | −7.7 | 1.1 | −79r | −184r | −176r | −133 | −77 | −90 | |
| Income tax | — | −0.0 | −0.0 | — | — | — | — | — | — | — | |
| Income from continuing operations | −0.7 | −2.3 | −7.7 | 1.1 | −79 | — | — | — | — | — | |
| Income from discontinued operations | 0.1 | 0.1 | −2.6 | 111 | −93 | — | — | — | — | — | |
| Net income attributable to shareholders | −0.6 | −2.2 | −10 | 112 | −172 | −184r | −176r | −133 | −77 | −90 | |
| Earnings per share, basic | -0.05 | -0.19 | -0.99r | 12.41 | -21.66r | -0.67 | -0.72 | -0.59 | -0.37 | -0.46 | |
| Earnings per share, diluted | -0.05 | -0.19 | -0.99r | 11.96 | -21.66r | -0.67 | -0.72 | -0.59 | -0.37 | -0.46 | |
| Shares, weighted average (basic) | 12 | 12r | 0.0r | 9.0 | 8.0r | 276 | 246 | — | — | — | |
| Shares, weighted average (diluted) | 12 | 12r | 0.0r | 9.4 | 8.0r | 276r | 246r | 225 | 206 | 196 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.5 | 5.1 | 4.3 | 38 | 65r | 80r | 161 | 162 | 127 | 132 | |
| Receivables | — | — | — | — | 36 | 32r | 24 | 11 | 4.3 | 4.5 | |
| Inventory | — | — | — | — | 7.6 | 8.0r | 12 | 3.3 | 1.5 | 1.1 | |
| Other current assets | 3.4 | 3.6 | 4.0 | 6.0 | 5.9r | 7.5r | 11 | 11 | 6.6 | 2.3 | |
| Current assets | 14 | 12 | 12 | 55 | 119 | 128r | 208 | 187 | 140 | 139 | |
| Property, plant and equipment | — | — | — | 0.1 | 0.8r | 1.9r | 2.5 | 0.5 | 0.4 | 0.5 | |
| Right-of-use (leased) assets | 5.3 | 6.1 | 6.9 | 7.6 | 8.2 | 9.6r | 10 | — | — | — | |
| Other intangible assets | 3.8 | 4.3 | 6.1 | 6.9 | 7.1r | 41r | 5.3 | 4.1 | 3.1 | 2.4 | |
| Non-current assets | — | — | — | — | — | — | — | 25 | 3.2 | 2.5 | |
| Total assets | 38 | 39 | 43 | 90 | 169 | 182r | 266 | 212 | 143 | 142 | |
| Accounts payable | 0.4 | 0.3 | 0.0 | 2.2 | 3.4r | 21r | 19 | 23 | 4.1 | 7.4 | |
| Debt due within a year | — | — | — | — | 188 | — | — | — | — | — | |
| Current liabilities | 4.8 | 5.2 | 6.9 | 47 | 253 | 59r | 53 | 41 | 13 | 15 | |
| Long-term debt | — | — | — | — | 0 | 238r | 195 | 73 | — | — | |
| Lease liabilities (non-current) | 5.1 | 5.5 | 6.5 | 7.4 | 8.1 | 8.7r | 9.1 | — | — | — | |
| Non-current liabilities | — | — | — | — | — | 246 | 204 | — | — | — | |
| Total liabilities | 11 | 11 | 14 | 55 | 263 | 306r | 257 | 114 | 13 | — | |
| Retained earnings | −952 | −952 | −950 | −939 | −1,051 | −879r | −695 | −519 | −387 | −310 | |
| Shareholders' equity | 27 | 27 | 29 | 35 | −94 | −124r | 9.2r | 98r | 130 | 127 | |
| Total liabilities and equity | 38 | 39 | 43 | 90 | 169 | 182r | 266 | 212 | 143 | 142 | |
| Shares outstanding | 12 | 12 | 12 | 9.5 | 8.6r | 300r | 271 | 240 | 216 | 197 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.4 | 0.5 | 0.9 | 1.2 | 0.7r | 4.1r | 1.4r | 0.3 | 0.2 | 0.1 | |
| Share-based compensation | 0.1 | 0.3 | 1.3 | 12 | 18 | 11r | 11r | 8.7 | 6.9 | 17 | |
| Cash from operating activities | 2.5 | 1.2 | −23 | 9.4 | −143 | −159r | −166r | −107 | −76 | −69 | |
| Capital expenditure | — | — | — | — | −0.0 | −0.2r | −2.5r | −0.2 | −0.1 | −0.4 | |
| Intangible assets bought | — | — | — | −0.4 | −2.2 | −1.4r | −1.4r | −1.1 | −0.8 | −0.8 | |
| Cash from investing activities | — | — | — | −0.4 | −2.2 | −1.6r | −24r | −21 | −0.8 | −1.3 | |
| Debt issued | — | — | — | — | — | — | — | 75 | — | — | |
| Debt repaid | — | — | — | −219 | −50 | — | −82 | — | — | — | |
| Shares issued | — | — | 3.2 | 2.5 | 184 | 32r | 77r | 90 | 69 | 135 | |
| Cash from financing activities | — | — | 3.2 | −235 | 130 | 81r | 189r | 163 | 73 | 137 | |
| Report | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
What TherapeuticsMD, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇺🇸 USA$2 M59%+60%
- Non-U.S.(total)$1 M41%+92%
As of Dec 31, 2025
Executive pay at TherapeuticsMD, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2024Marlan Walker | $759 K | $759 K | $120 K | $2 |
| 2023Marlan Walker | $1.0 M | $889 K | $685 K | $4 |
| 2022Hugh O’Dowd, Brian Bernick, Marlan Walker, Mark Glickman | $3.7 M | $420 K | $561 K | $9 |
As of Dec 31, 2024
Events at TherapeuticsMD, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 1 · Material agreement 1 · Shareholder vote 2 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K |
As of Nov 13, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2023 | $1 M | Private placement after listing | Under $2 million | 2 | equity | SEC |
| Oct 2022 | $7 M | Private placement after listing | $2 to $10 million | 6 | equity, options | SEC |
| Sep 2022 | $7 M | Private placement after listing | $2 to $10 million | 6 | equity, options | SEC |
| Jul 2022 | $15 M | Private placement after listing | $10 to $50 million | 6 | equity, options | SEC |
| Aug 2020 | $8 M | Private placement after listing | $2 to $10 million | 3 | options | SEC |
| Sep 2012 | $9 M | No. 1 | $2 to $10 million | 8 | equity | SEC |
Lobbying by TherapeuticsMD, Inc.#
$220 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.
- Health Issues4 reports
Lobbying firms hired in 2022
Sims Strategies, LLC $220 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $220 K | — | 4 |
| 2021 | $80 K | — | 2 |
| 2018 | $0 | — | 7 |
How TherapeuticsMD, Inc. compares in Pharmaceutical
- Market cap$23 M · higher than 9% of 393
- Revenue$3 M · higher than 4% of 328
- Net margin-6.4% · higher than 22% of 313
- Revenue growth71.6% · higher than 92% of 107
- Price / sales6.9× · lower than 18% of 219
- Price / book0.8× · lower than 87% of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| TherapeuticsMD, Inc.🇺🇸 | $23 M | — | -6.4% | +71.6% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Windlas Biotech Limited$214 M
- Venus Remedies Limited$215 M
How current the figures are
- Market cap:
- Oct 14, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at TherapeuticsMD, Inc.? Verify and update this profile — free
Show TherapeuticsMD, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.